Laureate Pharma, Inc. (11061029) renewed its agreement with Cytogen Corporation (Nasdaq: CYTO) for the cGMP manufacture of ProstaScint®, Cytogen's proprietary monoclonal antibody immunoconjugate that is used for imaging in patients diagnosed with prostate cancer.
Source: Laureate Pharma, Inc.
While Laureate Pharma will provide cGMP protein production, purification, conjugation of Cytogen's proprietary linker chelator and aseptic filling services in order to support Cytogen's commercial ProstaScint® requirements, other terms of the agreement were not disclosed.
Comment Preview